A Phase 2, multicenter, randomized, double-blind, placebo controlled, dose-ranging study to evaluate the efficacy and safety of SAR442970 in adults with moderate to severe Crohn’s disease
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Digestive Health and Surgery -
Location
-
Principal Investigator
Jennifer Seminerio-Diehl -
Sponsor
Sanofi
To assess the efficacy of different doses of SAR442970 on endoscopic response at the end of the induction period.
Enrollment Form
This study is currently enrolling.
